StocktoriaCelularity Inc CELU
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-38.41
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Gross profit | — | — | $6.8M | -$1.7M | $11.7M |
| Operating income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Net income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Operating cash flow | -$13.3M | -$6.4M | -$38.7M | -$137.9M | -$110.1M |
| Free cash flow | — | -$6.6M | -$39.7M | -$143.1M | -$116.3M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Shareholders' equity | -$38.1M | $8.8M | $41.0M | $198.9M | $99.4M |
| Ratios | |||||
| Gross margin | — | — | 29.7% | -9.4% | 54.8% |
| Operating margin | -230.9% | -70.7% | -844.4% | -142.4% | -511.2% |
| Net margin | -345.4% | -106.8% | -862.0% | 79.0% | -469.3% |
| FCF margin | — | -12.1% | -174.5% | -796.2% | -545.1% |
| Return on assets | -85.5% | -43.6% | -136.4% | 3.5% | -24.2% |
| Return on equity | 241.0% | -655.1% | -479.2% | 7.1% | -100.7% |
| Current ratio | 0.15 | 0.38 | 0.29 | 0.54 | 2.25 |
| Revenue growth | -51.0% | 138.1% | 26.7% | -15.7% | 49.4% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -38.41 (distress)
- Working capital / assets -0.638
- Retained earnings / assets -9.238
- EBIT / assets -0.571
- Equity / liabilities -0.262
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001752828 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.